皓元医药
(688131)
| 流通市值：28.65亿 | | | 总市值：49.82亿 |
| 流通股本：8648.52万 | | | 总股本：1.50亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 504,874,103.59 | 1,880,046,769.14 | 1,376,113,868.75 | 880,918,116.49 |
| 营业收入 | 504,874,103.59 | 1,880,046,769.14 | 1,376,113,868.75 | 880,918,116.49 |
| 二、营业总成本 | 465,236,626.83 | 1,672,706,963.81 | 1,187,610,757.49 | 739,063,197.83 |
| 营业成本 | 298,884,459.07 | 1,030,874,345.27 | 710,948,826.83 | 439,686,023.1 |
| 税金及附加 | 2,215,816.05 | 7,683,984.38 | 5,045,027 | 3,183,640.91 |
| 销售费用 | 43,702,221.81 | 158,023,343.9 | 101,515,038.95 | 62,776,816.93 |
| 管理费用 | 57,367,597.11 | 220,159,727.04 | 178,760,876 | 116,873,955.33 |
| 研发费用 | 53,593,858.98 | 224,115,452.97 | 171,910,538.46 | 108,386,978.55 |
| 财务费用 | 9,472,673.81 | 31,850,110.25 | 19,430,450.25 | 8,155,783.01 |
| 其中:利息费用 | 6,725,881.87 | 23,703,771.82 | 14,439,670.94 | 8,916,555.91 |
| 其中:利息收入 | 1,768,224.98 | 3,208,380.06 | 1,693,440.7 | 997,861.47 |
| 加:投资收益 | -2,138,700.84 | -4,772,110.67 | -2,671,345.29 | -1,202,530.97 |
| 资产处置收益 | 4,147.86 | 62,704.26 | 171,625.28 | 264,842.98 |
| 资产减值损失(新) | -22,127,152.32 | -83,999,102.8 | -53,886,522.86 | -34,922,808.72 |
| 信用减值损失(新) | -2,425,005.66 | -12,232,235.34 | -11,118,033.91 | -5,504,007.59 |
| 其他收益 | 3,643,034.56 | 21,929,523.47 | 12,797,843.24 | 10,874,160.98 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 16,593,800.36 | 128,328,584.25 | 133,796,677.72 | 111,364,575.34 |
| 加:营业外收入 | 129,653.98 | 2,340,274.15 | 1,160,355.94 | 573,628.3 |
| 减:营业外支出 | 23,324.83 | 2,476,314.44 | 2,159,078.59 | 1,866,914.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 16,700,129.51 | 128,192,543.96 | 132,797,955.07 | 110,071,289.61 |
| 减:所得税费用 | 163,959.67 | 1,884,939.97 | 16,039,854.48 | 16,196,786.06 |
| 六、净利润 | 16,536,169.84 | 126,307,603.99 | 116,758,100.59 | 93,874,503.55 |
| 持续经营净利润 | 16,536,169.84 | 126,307,603.99 | 116,758,100.59 | 93,874,503.55 |
| 归属于母公司股东的净利润 | 16,757,351.46 | 127,449,113.65 | 118,164,770.88 | 94,855,976.25 |
| 少数股东损益 | -221,181.62 | -1,141,509.66 | -1,406,670.29 | -981,472.7 |
| (一)基本每股收益 | 0.11 | 0.85 | 0.79 | 0.63 |
| (二)稀释每股收益 | 0.11 | 0.85 | 0.79 | 0.63 |
| 八、其他综合收益 | 347,032.14 | 827,004.88 | 2,701,650.75 | 6,511,856.68 |
| 归属于母公司股东的其他综合收益 | 347,032.14 | 827,004.88 | 2,701,650.75 | 6,511,856.68 |
| 九、综合收益总额 | 16,883,201.98 | 127,134,608.87 | 119,459,751.34 | 100,386,360.23 |
| 归属于母公司股东的综合收益总额 | 17,104,383.6 | 128,276,118.53 | 120,866,421.63 | 101,367,832.93 |
| 归属于少数股东的综合收益总额 | -221,181.62 | -1,141,509.66 | -1,406,670.29 | -981,472.7 |
| 公告日期 | 2024-04-30 | 2024-04-25 | 2023-10-31 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |